Exelixis Building A Pipeline Out Of A Product, Unveils Cabozantinib Activity Across Tumor Types At ASCO
Executive Summary
Exelixis Inc. is set to file the first NDA for its dual MET/VEGF2 inhibitor cabozantinib by the end of the year, but as that project winds down, plans for a suite of new indications are in the works as the company tries to leverage its asset as fully as possible.
You may also be interested in...
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.
Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question
Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.
Exelixis' Lead-In Trial Design Evaluates Cabozantinib Disease Activity Against Multiple Cancers At 12 Weeks
Novel adaptive randomized discontinuation design tested cabozantinib in nine tumor types, isolated best opportunities faster than traditional randomization.